Indication of Hyperhomocysteinemia in Type 2 Diabetes Mellitus Patients with Cardiovascular Complications

BioSight Pub Date : 2024-01-15 DOI:10.46568/bios.v5i1.149
Afsheen Sardar, J. Alam, A. Hussain, S. R. Mahmood, M. Ansari, M. Ansari
{"title":"Indication of Hyperhomocysteinemia in Type 2 Diabetes Mellitus Patients with Cardiovascular Complications","authors":"Afsheen Sardar, J. Alam, A. Hussain, S. R. Mahmood, M. Ansari, M. Ansari","doi":"10.46568/bios.v5i1.149","DOIUrl":null,"url":null,"abstract":"Introduction Cardiovascular disease (CVD) is one of the prominent causes of mortality in cases of chronic Type 2 diabetes mellitus (T2DM) patients and necessitates improving risk categorization. There are few available biomarkers that can assess preceding or current glycemic and cardiac status, but not prognosis. Serum homocysteine (Hcy) has been indicated and reported to be a likely biomarker that can detect cardiovascular complication in patients with T2DM. Methodology Present study details the comparative analysis of several biochemical and metabolic biomarkers including Hcy in T2DM patients with and without CVD complications. A total of eighty patients, n = 40 each in T2DM with CVD and T2DM without CVD, were included in the study.  Patient’s preparation, blood sample collection and analyses of all biochemical, metabolic markers including Hcy were performed as per standard protocols.  One way ANOVA was used for independent measures including Tukey HSD with level of significance at P< 0.05. Results Indication of hyperhomocysteinemia, was significantly apparent in patients with T2DM who have CVD, as compared to those with T2DM without CVD.  All other biochemical and metabolic parameters manifested marked significant (P< 0.00001) elevations, which was more perceptible in T2DM CVD as compared to T2DM non CVD. Clinical relevance of high Hcy in blood in patients with T2DM CVD thus suggested being prominent risk factor for proceeding renal and cardiac complications.","PeriodicalId":516564,"journal":{"name":"BioSight","volume":"76 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioSight","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46568/bios.v5i1.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction Cardiovascular disease (CVD) is one of the prominent causes of mortality in cases of chronic Type 2 diabetes mellitus (T2DM) patients and necessitates improving risk categorization. There are few available biomarkers that can assess preceding or current glycemic and cardiac status, but not prognosis. Serum homocysteine (Hcy) has been indicated and reported to be a likely biomarker that can detect cardiovascular complication in patients with T2DM. Methodology Present study details the comparative analysis of several biochemical and metabolic biomarkers including Hcy in T2DM patients with and without CVD complications. A total of eighty patients, n = 40 each in T2DM with CVD and T2DM without CVD, were included in the study.  Patient’s preparation, blood sample collection and analyses of all biochemical, metabolic markers including Hcy were performed as per standard protocols.  One way ANOVA was used for independent measures including Tukey HSD with level of significance at P< 0.05. Results Indication of hyperhomocysteinemia, was significantly apparent in patients with T2DM who have CVD, as compared to those with T2DM without CVD.  All other biochemical and metabolic parameters manifested marked significant (P< 0.00001) elevations, which was more perceptible in T2DM CVD as compared to T2DM non CVD. Clinical relevance of high Hcy in blood in patients with T2DM CVD thus suggested being prominent risk factor for proceeding renal and cardiac complications.
高同型半胱氨酸血症在心血管并发症的 2 型糖尿病患者中的适应症
导言心血管疾病(CVD)是慢性 2 型糖尿病(T2DM)患者死亡的主要原因之一,因此有必要改进风险分类。目前只有少数生物标志物可以评估之前或当前的血糖和心脏状况,但无法评估预后。据报道,血清同型半胱氨酸(Hcy)可能是检测 T2DM 患者心血管并发症的生物标志物。方法 本研究详细分析了包括 Hcy 在内的几种生化和代谢生物标记物在患有和未患有心血管疾病并发症的 T2DM 患者中的对比情况。研究共纳入 80 例患者,其中有心血管疾病的 T2DM 患者和无心血管疾病的 T2DM 患者各 40 例。 患者的准备工作、血样采集以及包括 Hcy 在内的所有生化和代谢指标的分析均按标准方案进行。 采用单因素方差分析进行独立测量,包括 Tukey HSD,显著性水平为 P<0.05。结果 与未患有心血管疾病的 T2DM 患者相比,患有心血管疾病的 T2DM 患者高同型半胱氨酸血症的迹象明显。 所有其他生化和代谢参数都有明显的升高(P< 0.00001),与非心血管疾病的 T2DM 患者相比,心血管疾病的 T2DM 患者的升高更为明显。因此,T2DM 心血管疾病患者血液中高 Hcy 的临床相关性表明,Hcy 是引发肾脏和心脏并发症的主要风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信